Accumulated seizure burden predicts neurodevelopmental outcome at 36 months of age in patients with tuberous sclerosis complex

Ähnliche Einträge

• Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program
  von: Arie Weinstock, et al.
  Veröffentlicht: (2024)
• The small molecule simufilam dose‐dependently attenuates the worsening of seizures in a mouse model of tuberous sclerosis complex
  von: Branden Stansley, et al.
  Veröffentlicht: (2026)
• Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle
  von: Mariana L. Pais, et al.
  Veröffentlicht: (2024)
• Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex
  von: Robert T. Wechsler, et al.
  Veröffentlicht: (2024)
• Distinct peripheral pro‐inflammatory profile associated with tuberous sclerosis complex and epilepsy
  von: Renaud Balthazard, et al.
  Veröffentlicht: (2025)